Preview

Rational Pharmacotherapy in Cardiology

Advanced search

USE OF FIXED COMBINATIONS OF RAMIPRIL AND HYDROCHLOROTHIAZIDE IN PATIENTS WITH ARTERIAL HYPERTENSION AND HIGH OR VERY HIGH CARDIOVASCULAR RISK (OPTIMIST 2 STUDY): RESULTS OF THE NONCOMPARATIVE STUDY

https://doi.org/10.20996/1819-6446-2011-7-4-426-430

Full Text:

Abstract

Aim. To evaluate efficacy and safety of treatment with fixed combination of ramipril and hydrochlorothiazide in patients with arterial hypertension (HT) 2-3 degree and high or very high cardiovascular risk in clinical practice. Material and methods. Patients with HT 2-3 degree and high or very high cardiovascular risk who had not reached target blood pressure (BP) levels with previous therapy (n=427) were included in open-label non-comparative multicenter phase IV study. Patients were treated with fixed combination of ramipril and hydrochlorothiazide during 8 weeks. The drug dose was increased and/or amlodipine was added in case of insufficient antihypertensive effect. Achievement of the target BP level (<130/80 mmHg) and therapy safety were assessed. Results. 420 patients (98.4%) completed the study. After 8 weeks 273 (65%) patients had a two-component therapy (fixed combination of ramipril and hydrochlorothiazide), 147 (35%) patients — triple therapy (ramipril, hydrochlorothiazide and amlodipine). The target BP level was achieved in 408 (97.14%) patients and it was not reached in 12 (2.86%) patients. 7 patients were dropped out from the study: 4 — because of adverse events (dry cough), 3 — due to violation of study protocol. Both patients and doctors considered fixed ramipril and hydrochlorothiazide combination as effective and well tolerable one.  Conclusion. Ramipril and hydrochlorothiazide fixed combination provides an achievement of the target BP level in the most of HT patients.

About the Authors

I. A. Velizhanina
Branch of Research Institute of Cardiology of the Siberian Branch of Russian Academy of Medical Sciences «Tyumen cardiology center»
Russian Federation


L. I. Gapon
Branch of Research Institute of Cardiology of the Siberian Branch of Russian Academy of Medical Sciences «Tyumen cardiology center»
Russian Federation


E. S. Velizhanina
Branch of Research Institute of Cardiology of the Siberian Branch of Russian Academy of Medical Sciences «Tyumen cardiology center»
Russian Federation


A. V. Rudakov
Branch of Research Institute of Cardiology of the Siberian Branch of Russian Academy of Medical Sciences «Tyumen cardiology center»
Russian Federation


T. S. Zhupanova
Branch of Research Institute of Cardiology of the Siberian Branch of Russian Academy of Medical Sciences «Tyumen cardiology center»
Russian Federation


References

1. Shal'nova S., Kukushkin S., Monoshkina E., Timofeeva T. Arterial hypertension and adherence to therapy. Vrach 2009; 12; 39-42. Russian (Шальнова С., Кукушкин С., Моношкина Е., Тимофеева Т. Артериальная гипертония и приверженность терапии. Врач 2009; 12; 39-42).

2. National guidelines for diagnosis and treatment of hypertension. The Experts Committee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 2:1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Комитет экспертов РМОАГ и ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2:1-32).

3. Kobalava Z.D., Kotovskaya J.V. Implication of the fixed combinations in the hypertension treatment. Rational Pharmacother Card 2010;6(4):550-557. Russian (Кобалава Ж.Д., Котовская Ю.В. Место ком-бинированной терапии с использованием фиксированных комбинаций в лечении артериальной гипертонии. Рациональная фармакотерапия в кардиологии; 6(4): 550 – 557).

4. Leonova M.V., Belousov D.Yu., analysis Group of PIFAGOR study. The first Russian pharmacoepidemiological study of hypertension. Kachestvennaya klinicheskaya praktika 2002; 3: 47-53. Russian (Леонова М.В., Белоусов Д.Ю., аналитическая группа исследования ПИФАГОР. Первое Российское фармакоэпидемиологическое исследование артериальной гипертонии. Качественная клиническая практика 2002; 3: 47-53).

5. Leonova M.V., Belousov D.Yu., Shteynberg L.L., analysis Group of PIFAGOR study. Analysis of the medical practice of antihypertensive therapy in Russia (according to a study PYTHAGOR III). Farmateka 2009;12: 98-103. Russian (Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л., аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в Рос-сии (по данным исследования ПИФАГОР III). Фарматека 2009;12: 98-103).

6. Wrignt J.T., Bakris G. Greene T. et al. Effect of blood pressure lowering and antihypertensive drug class on progressione of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288(19): 2421-2431.

7. Kaplan N.M. The CARE Study: a postmarketing evaluation of ramipril in 11 100 patients. The clinical Altace Real World Efficacy(CARE) Investigators. Сlin Ther 1996; 18(4): 658-70.

8. Agabiti-Rosei E., Ambrosioni E., Dal Palu С. et al. Ramipril cardioprotective evaluation study on behalf oF the RACE study group. J Hypertens 1995; 13: 1325-1334.

9. The Heart Outcomes Prevention Evaluation study Investigators. Effects of angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.

10. Lüders S., Schrader J., Berger J. et al. The PHARAO study: prevention of hypertension with the angiotensin-

11. converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26(7):1487-96.

12. ALLHAT Officers and Coordinators for The ALLHAT Collaborative Research Groopp Major outcomes high – risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium chanel blocker vs diuretic The Antihypertensive and Lipid –Lowering Treatment Prevent Heart At-tact Trial( ALLHAT). JAMA 2002; 288(23): 2981-2997.

13. Law M., Waid N., Morris J., Jordan R. Value of low dose combination treatment with blood pressure lovering drugs analisis of 354 randomised trials. BMJ 2003; 326(7404): 1427.

14. Chazova I.E., Ratova L.G. Combination therapy of hypertension. In: Chazov E.I., Chazova I.E., editors. Guidelines for hypertension. Moscow: Media Medika; 2005; 655—677. Russian (Чазова И.Е., Ра-това Л.Г. Комбинированная терапия артериальной гипертонии. В: Чазов Е.И., Чазова И.Е., редакторы. Руководство по артериальной гипертонии. М: Медиа Медика; 2005; 655—677).

15. Psaty B. Lumley T. Furberg C. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003; 289; 2534-44.

16. Kolos I.P., Martynyuk T.V., Safaryan A.S. et al. The study of efficacy of angiotensin converting enzyme inhibitor ramipril and its combination with hydrochlorothiazide in patients with hypertension and overweight: the KhARIZMA study. Kardiovaskulyarnaya terapiya i profilaktika 2008; 2; 65-71. Russian (Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензин-превращающего фермента рамиприлом и его комбинации с гидрохлортиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследование ХАРИЗМА. Кардиоваскулярная терапия и профилактика 2008; 2; 65-71).

17. Chazova I.E., Martynyuk T.V., Nebieridze D.V. et al. Comparative efficacy of different doses of fixed combinations of ramipril andhydrochlorthiazide. Kardiovaskulyarnaya terapiya i profilaktika 2010; 9(4); 25-31. Russian (Чазова И.Е., Мартынюк Т.В., Небиеридзе Д.В. и др. Сравнительная эффективность лечения фиксированными комбинациями различных доз рамиприла и гидрохлортиазида. Кардиоваскулярная терапия и профилактика 2010; 9(4); 25-31).

18. Fomin V.V., Moiseev S.V. Ramipril D is the fixed combination of antihypertensive drugs. Klinicheskaya farmakologiya i terapiya 2010;19(4) 62-66. Russian (Фомин В.В., Моисеев С.В. Рамиприл Д — фиксированный комбинированный антигипертензивный препарат. Клиническая фармакология и терапия 2010;19(4): 62-66).


For citation:


Velizhanina I.A., Gapon L.I., Velizhanina E.S., Rudakov A.V., Zhupanova T.S. USE OF FIXED COMBINATIONS OF RAMIPRIL AND HYDROCHLOROTHIAZIDE IN PATIENTS WITH ARTERIAL HYPERTENSION AND HIGH OR VERY HIGH CARDIOVASCULAR RISK (OPTIMIST 2 STUDY): RESULTS OF THE NONCOMPARATIVE STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(4):426-430. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-426-430

Views: 370


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)